Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05027490
Other study ID # 69HCL21_0409
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 27, 2022
Est. completion date September 21, 2023

Study information

Verified date October 2023
Source Hospices Civils de Lyon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Although it has been established that the perception of food and eating and cooking habits change during cancer and its treatment, quality of life related to meals, which is an indicator of the psychobiological and physiological well-being of patients in their relationship to food, has been little studied in the pathological context, and particularly in patients undergoing chemotherapy. Beyond its biological role, food plays a significant psychobiological and social role, as shown by a series of qualitative studies based on interviews with patients. Following a cancer diagnosis, loss of appetite, difficulty in sharing a meal with the family, and reduced pleasure in eating disrupt the patient's relationship with his or her food. Thus, side effects such as fatigue, nausea and vomiting, and alterations in taste and smell induced by chemotherapy will affect patients' eating behavior, increasing the risk of deteriorating their quality of life with food. As these side effects are less known and therefore less expected by patients, they often lack the information and tools necessary to understand them. The present study proposes a support for cancer patients treated by chemotherapy in order to improve their quality of life related to meals, and thus keep the pleasure of eating and reduce the risks of malnutrition. This support will consist of a guide provided to patients, in which they will have information on the functioning of the sensory systems involved in the eating experience, advice and culinary tips to adapt foods to their sensory disorders, and recipes that can be adapted in mild (for patients with hypersensitivity to tastes/smells), accentuated (for patients with hypersensitivity to tastes/smells) and enriched (for patients at risk of denutrition) versions. In addition, their sensory abilities will be assessed at the beginning of the study by psychophysical tests, then between each chemotherapy via a telephone interview (self-reported sensory abilities), and they will benefit from orientation according to the test results. This work will be a first action to improve the quality of life related to the meal by information, follow-up, and adaptation of the meals to the sensory performances of each patient.


Recruitment information / eligibility

Status Completed
Enrollment 209
Est. completion date September 21, 2023
Est. primary completion date September 21, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Major patient with one of the following 3 types of cancer: - Stage 4 lung cancer (TNM 7 or 8). The indication for immunotherapy in addition to first line chemotherapy will not be a criterion for non-inclusion patients - histologically or cytologically proven localized breast cancer cytologically proven - Gynecological cancer (ovarian cancer or uterine cancer) stage III-IV without functional digestive signs related to the tumor disease - Patient with a body mass index (BMI) between 18 Kg/m² and 35 Kg/m². - Patient for whom the indication for treatment with a first line of intravenous chemotherapy (+/- targeted therapy) has been accepted by multidisciplinary meeting. - Patient naive to previous chemotherapy. - Life expectancy > 3 months. - Patient with written informed consent - Patient affiliated to a French social security system. Exclusion Criteria: - Patient under 18 years - Patient who had another malignancy within the last 3 years years, with the exception of carcinoma in situ of the cervix or cervical carcinoma in situ or adequately treated squamous cell carcinoma of the skin adequately treated, or basal cell skin cancer.This cancer must be adequately controlled. - Patients with symptomatic brain and/or meningeal metastases. - Patients with symptomatic mucositis. - Patients suffering or having suffered from an ear, nose and throat disease or oeso-gastro intestinal pathology interfering with the food intake. - Patients suffering from digestive disorders such as nausea prior to any cancer treatment. - Indication of concomitant radiotherapy or immunotherapy treatment alone. - Patients with a known food allergy or intolerance - Patient with diagnosed partial or total ageusia. - Patient with diagnosed partial or total anosmia. - Patient having used artificial feeding in the 2 months prior to inclusion. - Patient who has lost more than 10% of baseline weight in the 2 months prior to inclusion. - Patient unable to be regularly followed for any reason (geographical, family, social, psychological,...). - Patient deprived of liberty or placed under guardianship or legal protection. - Pregnant or breastfeeding woman

Study Design


Intervention

Other:
CANUT support
CANUT support includes delivery of the CANUT guide (food guide developed by Paul Bocuse Institute from previous results) ; it will be given to patient with explanations about the use of the guide. This also includes 2 calls from a dietician, performed between the 1st and the 3rd chemotherapy cycle to help patient personally with their food side effects.
Anthropometric measures
These measures include weight, waist size, hip size and brachial circumference
Prehension strength measurement
Prehension strength will be assessed thanks to a hand grip device, that makes it possible to measure strength of all fingers, hands, wrists and forearms muscles
Behavioral:
QVA Questionnaire
Food quality of life questionnaire
QLQ C30 Questionnaire
Quality of Life questionnaire Core 30
Scratch & Snif Test
The Scratch & Snif Test is used to assess olfactory capacities : patient has to scratch a box on a card, smell it and recognize the scent amongst a list of propositions
Taste Strip Test
The Taste Strip Test is used to assess taste capacities : strips impregnated with different concentrations of the 5 basic taste qualities (sweet, sour, acid, bitter, umami) are successively placed on patient's tongue ; patient has to identify the taste bit by bit.
24 H feed back questionnaire
This questionnaire describes patient's food and drink intakes during the last 24 ours
Condiment questionnaire
This questionnaire used to assess condiments consumption
Tobacco questionnaire
This questionnaire used to assess tobacco consumption
Other:
Nutrition interview
This interview will be conducted by a dietician

Locations

Country Name City State
France Hôpital Louis Pradel, Service gynécologie Bron
France Hôpital Louis Pradel, Service pneumologie Bron
France Infirmerie Protestante Caluire-et-Cuire
France Centre Léon Bérard, service gynécologie Lyon
France Centre Léon Bérard, service pneumologie Lyon
France Hôpital de la Croix Rousse, service pneumologie Lyon
France Centre hospitalo-universitaire de Lyon Sud, service Oncologie médicale Pierre-Bénite
France Centre hospitalo-universitaire de Lyon Sud, service pneumologie Pierre-Bénite
France CHU St Etienne, Saint-Étienne
France CH de Valence Valence

Sponsors (1)

Lead Sponsor Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary QVA questionnaire score difference between the 2 arms The main endpoint of CANUT-2 is the comparison of the overall score of the food quality of life questionnaire (Qualité de Vie Alimentaire QVA) between patients who received CANUT support and those who did not receive the CANUT support. The comparison is performed at the time of V2 i.e. after 4 cycles of chemotherapy treatment, corresponding with the end of study follow-up. At the end of study follow-up, up to 12 weeks
Secondary QVA questionnaire score Food questionnaire score QVA will be compared for each subsection between the 2 groups and between V1 (inclusion) and V2 (after 4 cycles of chemotherapy), according to the type of cancer. At the end of study follow-up, up to 12 weeks
Secondary QLQ-C30 score Quality of life questionnaire score QLQ-C30 will be compared between the 2 arms and between V1 and V2, according to the type of cancer At the end of study follow-up, up to 12 weeks
Secondary Weight Anthropometric parameters (weight, waist size, hip size and brachial circumference) associated with 24 H feedback questionnaire score and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer. At the end of study follow-up, up to 12 weeks
Secondary waist size Anthropometric parameters (weight, waist size, hip size and brachial circumference) associated with 24 H feedback questionnaire score and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer. At the end of study follow-up, up to 12 weeks
Secondary hip size Anthropometric parameters (weight, waist size, hip size and brachial circumference) associated with 24 H feedback questionnaire score and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer. At the end of study follow-up, up to 12 weeks
Secondary brachial circumference Anthropometric parameters (weight, waist size, hip size and brachial circumference) associated with 24 H feedback questionnaire score and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer. At the end of study follow-up, up to 12 weeks
Secondary Prehension strength This parameter, associated with anthropometric parameters and 24 H feedback questionnaire score, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer At the end of study follow-up, up to 12 weeks
Secondary 24 H feedback questionnaire score This parameter, associated with anthropometric parameters and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer At the end of study follow-up, up to 12 weeks
Secondary Olfactory capacities Olfactory capacities will be assessed thanks to the Scratch & Snif Test At the end of study follow-up, up to 12 weeks
Secondary Taste capacities Taste capacities will be assessed thanks to the Taste Strip Test At the end of study follow-up, up to 12 weeks
Secondary Trigeminal sensitivity Trigeminal sensitivity will be assessed thanks to a trigeminal sensitivity test At the end of study follow-up, up to 12 weeks
Secondary Use of CANUT guide Changes in the frequency of use of the CANUT guide At the end of study follow-up, up to 12 weeks
Secondary Patient typology Determining patient typology according to CITAS (Chemotherapy-induced Taste Alteration Scale) scale At the end of study follow-up, up to 12 weeks
Secondary Patient satisfaction Determining patient satisfaction using a satisfaction questionnaire At the end of study follow-up, up to 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A